🟡 Medium ImpactPharma
Biocon's partner secures insulin tenders in Malaysia
Biocon's partner Duopharma Biotech secures key insulin tenders in Malaysia. This reinforces Biocon’s footprint in diabetes care abroad. The win highlights growing international demand for its insulin products. No financials disclosed, but strategic impact is positive.
📊 STOCKS: BIOCON | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #DiabetesCare
#DiabetesCare#Malaysia#Tenders#Partnership
Stocks mentioned
⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Next article
bajaj auto hit by ransomware attack →Trade smarter on NSE
Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.
Start for ₹1 →